You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 96 No. 4, OCTOBER 1955 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Nitrofurantoin

Clinical and Laboratory Studies in Urinary Tract Infections

WILLIAM A. RICHARDS, M.D.; EGON RISS, M.D.; EDWARD H. KASS, M.D., Ph.D.; MAXWELL FINLAND, M.D.

AMA Arch Intern Med. 1955;96(4):437-450.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Nitrofurantoin,* N- (5-nitro-2-furfurylidene)-1-aminohydantoin, is one of a series of substituted furan derivatives having a nitro group at the 5- position in the furan ring and possessing antibacterial properties.{dagger} It is the first of this series of compounds to be used in human infections. After oral administration it appears in significant concentrations only in the urine {ddagger} its usefulness has, therefore, been limited to infections of the urinary tract, for which it has been used by a number of workers.§

Dodd and Stillman,17 in 1944, showed that the addition of a nitro group in the 5- position to a large number of substituted furan derivatives markedly enhanced their antibacterial properties. Cramer and Dodd 18 extended these studies and showed that the action of compounds of this type is bacteriostatic but that under certain circumstances, or at higher concentrations, some of them may also be bactericidal. Enhancement of the antibacterial effect . . . [Full Text PDF of this Article]


Author Affiliations

Boston

From the Thorndike Memorial Laboratory, Second and Fourth Medical Services (Harvard), Boston City Hospital, and the Department of Medicine, Harvard Medical School.


Footnotes

Submitted for publication July 25, 1955.

Aided by a grant from the U. S. Public Health Service.

Supplied under the trade-mark Furadantin by Eaton Laboratories, Norwich, N. Y.

t The first report of the isolation of nitrofurantoin was made by Paul, H. E.; Hayes, K., and Bender, R. C.: Urinary Excretion Studies with Furadantin (N- [5-Nitro-2-Furfurilidine] 1-aminohydantoin) and Selected Nitrofurans, read before Section C (Chemistry) of the American Association for the Advancement of Science, Boston, Dec. 27, 1953.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1955 American Medical Association. All Rights Reserved.